SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 5/26/2015 10:30:43 PM - Followers: 36 - Board type: Free - Posts Today: 1

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for GALT
GALT News: Current Report Filing (8-k) 08:02 AM
GALT News: Confidential Treatment Order (ct Order) 05/26/2015 03:56:01 PM
GALT News: Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders 05/15/2015 08:00:00 AM
GALT News: Current Report Filing (8-k) 05/14/2015 08:02:18 AM
GALT News: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam 05/14/2015 08:00:00 AM
News News Alert: Current Report Filing (8-k) 05/27/2015 08:02:24 AM
PostSubject
#2002   new drug application maybe ? oldsport 05/27/15 01:41:47 PM
#2001   You just need to trust Peter Traber. ;-) thefamilyman 05/26/15 10:30:43 PM
#2000   Any guesses as to what the CTO is Darwinian 05/26/15 08:41:42 PM
#1999   Good information on the conference call today. thefamilyman 05/21/15 01:31:43 PM
#1998   Galtw Cbdpotential 05/15/15 09:41:34 PM
#1997   Q. for SH meeting. If the IRAHopeful 05/15/15 04:00:40 PM
#1996   Costs of trials, financing plans, what sort of Adi2 05/15/15 12:37:15 PM
#1995   Anyone got any poignant questions for the SH Darwinian 05/15/15 11:47:43 AM
#1994   They are at phase 2b... Adi2 05/15/15 05:49:00 AM
#1993   The perspective given by Thefamilyman is valid, including JERZYATP1 05/14/15 04:19:13 PM
#1992   The CX Trial requires measuring hepatic venous pressure Tesla1 05/14/15 01:15:27 PM
#1991   1) As my previous posts on this board thefamilyman 05/14/15 12:15:05 PM
#1990   Didn't know this study was going on. Sounds Darwinian 05/14/15 12:13:30 PM
#1989   It was a serious question thanks for the XenaLives 05/14/15 11:55:00 AM
#1988   The Providence Portland Medical Center is funding the DirectionalDriller 05/14/15 11:51:19 AM
#1987   If this is a "Pump & Dump", then thefamilyman 05/14/15 11:26:59 AM
#1986   any opinion on peter traber s shotgun wedding ? oldsport 05/14/15 09:39:26 AM
#1985   midasolam and grmd2 study result out... oldsport 05/14/15 09:01:54 AM
#1984   galt is in phase 2 and all data oldsport 05/14/15 07:32:46 AM
#1983   "This is playing like a P&D." sunspotter 05/14/15 03:09:18 AM
#1981   This is playing like a P&D. XenaLives 05/14/15 12:34:02 AM
#1980   Thanks. If so, Tesla1, we just lost a Adi2 05/13/15 10:52:34 PM
#1979   I stand corrected. It's tough losing your mind. IRAHopeful 05/13/15 06:55:08 PM
#1978   i thought exp date is march 23, 2017... oldsport 05/13/15 05:11:49 PM
#1977   IRAH: Not that it matters by much but Tesla1 05/13/15 05:08:55 PM
#1976   looks like current warrant pps is fair value... oldsport 05/13/15 04:43:28 PM
#1975   Yes. Thanks. That's an important bit of information ;•) Darwinian 05/13/15 04:23:43 PM
#1974   Adi2: IMO the type of chemical characterization Tesla1 05/13/15 02:50:28 PM
#1973   Galt Facebook/Twitter has been making at least a a_list_alias 05/13/15 02:11:04 PM
#1972   It may be that La Jolla Pharmaceutical (NASDAQ:LJPC) Adi2 05/13/15 02:01:35 PM
#1971   The warrants expire on or about March 17, 2017. IRAHopeful 05/13/15 01:14:57 PM
#1970   My understanding is that a broker needs to Darwinian 05/13/15 11:23:56 AM
#1969   how does one exercise warrants oldsport 05/13/15 10:59:59 AM
#1968   Warrants are a steal right now. I am Darwinian 05/13/15 10:32:19 AM
#1967   My opinion is that the shares would recover Tesla1 05/12/15 07:16:00 PM
#1965   The most important thing (IMO) ever posted by biotech2010 05/12/15 10:24:29 AM
#1964   Same BS on a new day... Ah, publicity! zest 05/11/15 08:13:05 PM
#1963   Rickey: You're off to a fine start. I'm JERZYATP1 05/11/15 04:58:39 PM
#1962   I've been following this a looong time. IRAHopeful 05/11/15 04:36:54 PM
#1961   My take on it is NO delay... thefamilyman 05/11/15 02:37:39 PM
#1960   Ahh. I see that, disappointing about the SPA.I Darwinian 05/11/15 11:45:56 AM
#1959   the next bounce on this thing is gonna oldsport 05/11/15 11:17:59 AM
#1958   forget cx trial ... delays oldsport 05/11/15 11:08:43 AM
#1957   s/b enough to get us through the FX Darwinian 05/11/15 11:03:25 AM
#1956   financial and update are out... $29mil cash reserve oldsport 05/11/15 08:54:55 AM
#1955   Thanks for that post ricky... 123tom 05/11/15 12:01:02 AM
#1954   given the current $galt pps , anyone out oldsport 05/10/15 11:08:50 PM
#1953   Thanks, Tesla. Darwinian 05/10/15 08:39:35 PM
#1952   The turtle wins the race. Galt is rickyricks 05/10/15 02:34:28 PM
#1951   Biotech,I value your fundamental understanding. 123tom 05/10/15 12:29:54 AM
PostSubject